Retina
273-288 of 340
BY: Amy S. Babiuch, MD
Caroline Baumal, MD
David Eichenbaum, MD
Roger A. Goldberg, MD, MBA
Nancy M. Holekamp, MD
Amy S. Babiuch, MD
Caroline Baumal, MD
David Eichenbaum, MD
Roger A. Goldberg, MD, MBA
Nancy M. Holekamp, MD
CME/CECurrent and Future Treatments in Age-Related Macular Degeneration: 2019 Year in Review
1.00 creditCharles C. Wykoff, MD, PhD
Audina Berrocal, MD
Geeta A. Lalwani, MD
Andrew Moshfeghi, MD, MBA
Anton Orlin, MD
Yoshihiro Yonekawa, MD
Aleksandra V. Rachitskaya, MD
Jorge Fortun, MD
Mitul Mehta, MD
Hemang K. Pandya, MD
Veeral Sheth, MD
Lejla Vajzovic, MD
Jeremy Wolfe, MD
Aleksandra V. Rachitskaya, MD
Jorge Fortun, MD
Mitul Mehta, MD
Hemang K. Pandya, MD
Veeral Sheth, MD
Lejla Vajzovic, MD
Jeremy Wolfe, MD
Aleksandra V. Rachitskaya, MD
Jorge Fortun, MD
Mitul Mehta, MD
Hemang K. Pandya, MD
Veeral Sheth, MD
Lejla Vajzovic, MD
Jeremy Wolfe, MD
Jorge Fortun, MD
Mitul Mehta, MD
Hemang Pandya, MD
Veeral Sheth, MD
Arshad M. Khanani, MD, MA
David Boyer, MD
Allen Ho, MD
Nancy Holekamp, MD
Arshad M. Khanani, MD, MA
Nancy Holekamp, MD
Jonathan Prenner, MD
Michael Singer, MD
- CME/CE Broadcast Replay
Advances in Gene Therapies for Retinal Disorders: Individualized Management of Patients
1.25 creditsAllen C. Ho, MD
Robert Avery, MD
Pravin U. Dugel, MD
Jeffrey S. Heier, MD
- CME/CE Broadcast Replay
What's Changing: Market Access Challenges with Anti-VEGF Therapies - Webcast
1.00 creditNathan Steinle, MD
Winston Wong, PharmD
Sean Goodale, CPA, MBA
- CME/CE
Addressing Barriers to Patient Care: Market Access Challenges With Anti-VEGF Therapies
1.00 creditNathtan Steinle, MD
Sean Goodale, CPA, MBA
Winston Wong, PharmD
Thomas A. Albini, MD
Nathan M. Radcliffe, MD
Aleksandra V. Rachitskaya, MD
Will Parke, MD
Anton Orlin, MD
Camila Ventura, MD, PhD
I. Paul Singh, MD
David Callanan, MD
Jonathan S. Myers, MD
Sumit Sharma, MD